In this article, we will take a look at the 5 Best Diversified Dividend Stocks to Buy Right Now. For deeper discussion and analysis, have a look at 13 Best Diversified Dividend Stocks to Buy Right Now.
Photo by Sharon McCutcheon on Unsplash
5. RTX Corporation (NYSE:RTX)
Number of Hedge Fund Holders: 79
On March 24, Erste Group analyst Hans Engel initiated coverage of RTX Corporation (NYSE:RTX) with a Buy rating. The firm said the company is benefiting from strong demand for engines, along with a broader increase in global defense spending.
On March 13, RTX announced it had completed a 26,000 square-foot expansion of its Redstone Raytheon Missile Integration Facility. The project was backed by a $115 million investment and is expected to lift the site’s integration and delivery capacity by more than 50%. It also expands the company’s presence in the state to over 2,200 employees.
Since opening in 2012, the Redstone Raytheon facility has become a key part of the company’s missile production and integration operations. It supports nine variants of the Standard Missile family, along with other advanced systems. The latest expansion reflects ongoing efforts to increase capacity and speed up production to meet both immediate and long-term demand for munitions.
RTX Corporation (NYSE:RTX) operates as an aerospace and defense company, providing systems and services to commercial, military, and government customers worldwide. It is organized into three segments: Collins Aerospace, Pratt & Whitney, and Raytheon.
4. Honeywell International Inc. (NASDAQ:HON)
Number of Hedge Fund Holders: 79
On March 26, Honeywell International Inc. (NASDAQ:HON) announced a collaboration with Rhombus, a cloud-based video management company, to expand its portfolio of cloud-connected security and access solutions. The partnership introduces new AI-powered video capabilities.
The move builds on Honeywell’s efforts to modernize building security, which started in 2024 with the acquisition of LenelS2. Through this collaboration, Honeywell and Rhombus plan to offer integrated access control and video management in a single cloud-based solution designed to be easy to deploy, scale, and manage. The combined offering will first be rolled out in North America, the United Kingdom, and Australia. Over time, the companies expect to expand globally, using their combined infrastructure and reach to serve organizations of different sizes with a unified security platform.
Honeywell International Inc. (NASDAQ:HON) is an integrated company serving a wide range of industries and regions. Its portfolio is supported by the Honeywell Accelerator operating system and the Honeywell Forge platform. The company provides solutions across aerospace, building automation, industrial automation, process automation, and process technology.
3. Corning Incorporated (NYSE:GLW)
Number of Hedge Fund Holders: 85
On March 31, Truist initiated coverage of Corning Incorporated (NYSE:GLW) with a Hold rating. It set a $125 price target on the stock. The firm said networking and hardware companies are closely tied to rising AI and cloud spending. It pointed out that US hyperscaler capex alone is expected to reach around $700 billion in 2026. The analyst said the firm is taking a more selective approach to the group, given relatively higher valuations. It named Arista Networks (ANET), Cisco (CSCO), HPE (HPE), and Motorola Solutions (MSI) as its preferred picks.
On March 23, BofA raised its price recommendation on Corning to $155 from $144. It reiterated a Buy rating on the shares. The firm said the higher target reflects increased confidence in the optical cycle and greater content per GPU in scale-out deployments.
Corning Incorporated (NYSE:GLW) operates as a materials science company. It is organized into segments, including Optical Communications, Display Technologies, Specialty Materials, Environmental Technologies, and Life Sciences.
2. The Procter & Gamble Company (NYSE:PG)
Number of Hedge Fund Holders: 90
On March 30, Deutsche Bank lowered its price recommendation on The Procter & Gamble Company (NYSE:PG) to $162 from $171. It reiterated a Hold rating on the shares. The firm noticed the “legitimate and widespread pressures building” across much of the consumer packaged goods industry, linked to the conflict in the Middle East. The analyst said the group underperformed in March. Cost inflation was the main concern, along with the risk of demand softening as consumers trade down. Currency movements also weighed on performance, according to the research note.
During the fiscal Q2 2026 earnings call, CFO Andre Schulten said the company’s guidance for fiscal 2026 remains unchanged. He noted that organic sales growth is still expected to come in roughly in line to up 4%. He also said global market growth across the company’s portfolio is expected to be around 2% on a value basis. Growth in the US is likely to be stronger as ongoing initiatives begin to show results.
On earnings, Schulten said core EPS is expected to increase about 4% year over year, implying a range of $6.83 to $7.09 per share. He added that the company plans to return a significant amount of cash to shareholders, with about $10 billion in dividends and roughly $5 billion in share repurchases, for a total of around $15 billion in fiscal 2026. He also noted that the outlook includes about $500 million in additional pre-tax costs tied to tariffs. The core effective tax rate is expected to be between 20% and 21%. Adjusted free cash flow productivity is projected in the range of 85% to 90%.
The Procter & Gamble Company (NYSE:PG) focuses on branded consumer packaged goods sold across global markets. Its segments include Beauty, Grooming, Health Care, Fabric & Home Care, and Baby, Feminine & Family Care. The company sells its products in approximately 180 countries and territories.
1. Johnson & Johnson (NYSE:JNJ)
Number of Hedge Fund Holders: 104
On March 30, Reuters reported that Royalty Pharma entered into a $500 million research and development agreement with Johnson & Johnson (NYSE:JNJ) to support an experimental antibody treatment for autoimmune diseases. Shares of JNJ moved up nearly 0.7% in premarket trading following the news.
The agreement will run through 2026 and 2027 and focuses on the development of JNJ-4804. The therapy is designed to target IL-23 and TNF, two immune pathways that play a role in autoimmune inflammation. Royalty Pharma CEO Pablo Legorreta said the treatment shows promise for patients dealing with chronic immune-related conditions. He also pointed out that the deal builds on the company’s earlier work in immunology, including investments in therapies targeting TNF.
Royalty Pharma already collects royalties on more than 35 commercial products. That list includes Biogen’s Tysabri and Johnson & Johnson’s Tremfya, both widely used in autoimmune treatments.
Johnson & Johnson (NYSE:JNJ) operates across the healthcare space, with businesses spanning Innovative Medicine and MedTech. It focuses on developing, manufacturing, and selling a broad range of healthcare products.
While we acknowledge the potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JNJ and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 14 Safest Stocks with Highest Dividends and Dividend Capture Strategy: 14 High Yield Stocks to Buy in April
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
